multiple myeloma

News

ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa

Can a new on-body injector version of Sanofi's Sarclisa help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma?

Oncology

Regeneron at ASCO 25: Advancing multiple myeloma treatment

News

Japan follows UK in GSK's comeback tour for Blenrep

The revitalisation of GSK's blood cancer therapy Blenrep continues with a second approval, in Japan, as a second-line treatment for multiple myeloma.

News

Italian decision sets up launch of Oncopeptides' Pepaxti

Oncopeptides hopes to reignite growth in multiple myeloma drug Pepaxti after getting reimbursement approval in Italy.

News

Survival data graph from the DREAMM-7 trial

ASH: Blenrep ups survival by 42% in multiple myeloma trial

GSK reveals the survival data that it reckons could return BCMA drug Blenrep to the forefront of multiple myeloma treatment.

Oncology

Driving innovation in multiple myeloma to improve the patien...

Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies.1

ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa

Regeneron at ASCO 25: Advancing multiple myeloma treatment

Japan follows UK in GSK's comeback tour for Blenrep

Italian decision sets up launch of Oncopeptides' Pepaxti

ASH: Blenrep ups survival by 42% in multiple myeloma trial

Driving innovation in multiple myeloma to improve the patien...

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

multiple myeloma

Editor's Picks